Ratings Neogen Corporation

Equities

NEOG

US6404911066

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
12.02 ^USD	-3.45%		-0.99%	-40.23%

Apr. 30	Neogen® Launches New Molecular Method for Detection of Two Salmonella Serotypes	CI
Apr. 18	Neogen Corporation Forms Genomics Relationship with Performance Food Group	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company has insufficient levels of profitability.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
NEOGEN CORPORATION	-40.23%	2.6B	C
ABBOTT LABORATORIES	-3.79%	184B	C+
MEDTRONIC PLC	-0.84%	108B	C
BECTON, DICKINSON AND COMPANY	-3.75%	67.8B	A
DEXCOM, INC.	+3.45%	51.05B	B-
CENCORA, INC.	+9.04%	44.67B	B-
HOYA CORPORATION	+3.40%	41.78B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+3.21%	26.78B	B
WEST PHARMACEUTICAL SERVICES, INC.	+3.66%	26.59B	A-
TERUMO CORPORATION	+15.23%	25.86B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes